Cargando…
The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients
BACKGROUND: As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease. There is some evidence that a higher modified Glasgow Prognostic Score (mGPS) may be associated with poorer survival in patients with p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686580/ https://www.ncbi.nlm.nih.gov/pubmed/23768149 http://dx.doi.org/10.1186/1471-2407-13-292 |
_version_ | 1782273794703884288 |
---|---|
author | Shafique, Kashif Proctor, Michael J McMillan, Donald C Leung, Hing Smith, Karen Sloan, Billy Morrison, David S |
author_facet | Shafique, Kashif Proctor, Michael J McMillan, Donald C Leung, Hing Smith, Karen Sloan, Billy Morrison, David S |
author_sort | Shafique, Kashif |
collection | PubMed |
description | BACKGROUND: As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease. There is some evidence that a higher modified Glasgow Prognostic Score (mGPS) may be associated with poorer survival in patients with prostate cancer but it is not known whether this is independent of other established prognostic factors. Therefore the aim of this study was to describe the relationship between mGPS and survival in patients with prostate cancer after adjustment for other prognostic factors. METHODS: Retrospective clinical series on patients in Glasgow, Scotland, for whom data from the Scottish Cancer Registry, including Gleason score, Prostate Specific Antigen (PSA), C-reactive protein (CRP) and albumin, six months prior to or following the diagnosis, were included in this study. The mGPS was constructed by combining CRP and albumin. Five-year and ten-year relative survival and relative excess risk of death were estimated by mGPS categories after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days. RESULTS: Seven hundred and forty four prostate cancer patients were identified; of these, 497 (66.8%) died during a maximum follow up of 11.9 years. Patients with mGPS of 2 had poorest 5-year and 10-year relative survival, of 32.6% and 18.8%, respectively. Raised mGPS also had a significant association with excess risk of death at five years (mGPS 2: Relative Excess Risk = 3.57, 95% CI 2.31-5.52) and ten years (mGPS 2: Relative Excess Risk = 3.42, 95% CI 2.25-5.21) after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days. CONCLUSIONS: The mGPS is an independent and objective prognostic indicator for survival of patients with prostate cancer. It may be useful in determining the clinical management of patients with prostate cancer in addition to established prognostic markers. |
format | Online Article Text |
id | pubmed-3686580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36865802013-06-20 The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients Shafique, Kashif Proctor, Michael J McMillan, Donald C Leung, Hing Smith, Karen Sloan, Billy Morrison, David S BMC Cancer Research Article BACKGROUND: As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease. There is some evidence that a higher modified Glasgow Prognostic Score (mGPS) may be associated with poorer survival in patients with prostate cancer but it is not known whether this is independent of other established prognostic factors. Therefore the aim of this study was to describe the relationship between mGPS and survival in patients with prostate cancer after adjustment for other prognostic factors. METHODS: Retrospective clinical series on patients in Glasgow, Scotland, for whom data from the Scottish Cancer Registry, including Gleason score, Prostate Specific Antigen (PSA), C-reactive protein (CRP) and albumin, six months prior to or following the diagnosis, were included in this study. The mGPS was constructed by combining CRP and albumin. Five-year and ten-year relative survival and relative excess risk of death were estimated by mGPS categories after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days. RESULTS: Seven hundred and forty four prostate cancer patients were identified; of these, 497 (66.8%) died during a maximum follow up of 11.9 years. Patients with mGPS of 2 had poorest 5-year and 10-year relative survival, of 32.6% and 18.8%, respectively. Raised mGPS also had a significant association with excess risk of death at five years (mGPS 2: Relative Excess Risk = 3.57, 95% CI 2.31-5.52) and ten years (mGPS 2: Relative Excess Risk = 3.42, 95% CI 2.25-5.21) after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days. CONCLUSIONS: The mGPS is an independent and objective prognostic indicator for survival of patients with prostate cancer. It may be useful in determining the clinical management of patients with prostate cancer in addition to established prognostic markers. BioMed Central 2013-06-17 /pmc/articles/PMC3686580/ /pubmed/23768149 http://dx.doi.org/10.1186/1471-2407-13-292 Text en Copyright © 2013 Shafique et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Shafique, Kashif Proctor, Michael J McMillan, Donald C Leung, Hing Smith, Karen Sloan, Billy Morrison, David S The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients |
title | The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients |
title_full | The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients |
title_fullStr | The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients |
title_full_unstemmed | The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients |
title_short | The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients |
title_sort | modified glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686580/ https://www.ncbi.nlm.nih.gov/pubmed/23768149 http://dx.doi.org/10.1186/1471-2407-13-292 |
work_keys_str_mv | AT shafiquekashif themodifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT proctormichaelj themodifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT mcmillandonaldc themodifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT leunghing themodifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT smithkaren themodifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT sloanbilly themodifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT morrisondavids themodifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT shafiquekashif modifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT proctormichaelj modifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT mcmillandonaldc modifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT leunghing modifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT smithkaren modifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT sloanbilly modifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients AT morrisondavids modifiedglasgowprognosticscoreinprostatecancerresultsfromaretrospectiveclinicalseriesof744patients |